The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-α

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1469-1478

  Oie, Shinji ^a,b   Ono, Mayumi ^a,c   Yano, Hirohisa ^c   Maruyama, Yuichiro ^a,c   Terada, Tadafumi ^b   Yamada, Yuji ^b,c   Ueno, Takato ^c   Kojiro, Masamichi ^c   Hirano, Kazuyuki ^d   Kuwano, Michihiko ^a,c  

^a KYUSHU UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Combination therapy; Hepatocellular carcinoma; Interferon receptor; Interferon ; Synergism

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; IFNAR1 PROTEIN, HUMAN; IFNAR2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BIOSYNTHESIS; CELL GROWTH; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; RECEPTOR, INTERFERON ALPHA-BETA; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 33947577494     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1469     Document Type: Article

References (33)

1. Cheung YC, Ko SF, Ng SH, Chan SC and Cheng YF: Survival outcome of lobar or segmental transcatheter arterial embolization with ethanol-lipiodol mixture in treating hepatocellular carcinoma. World J Gastroenterol 11: 2792-2795, 2005.
2. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, Kondo F and Saisho H: Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43: 458-464, 2005. (Pubitemid 41111427)
3. Kawamoto C, Ido K, Isoda N, Hozumi M, Nagamine N, Ono K, Sato Y, Kobayashi Y, Nagase G and Sugano K: Long-term outcomes for patients with solitary hepatocellular carcinoma treated by laparoscopic microwave coagulation. Cancer 103: 985-993, 2005. (Pubitemid 40270075)
4. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T and Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103: 1201-1209, 2005.
5. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235, 2005. (Pubitemid 40613379)
6. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K and Monden M: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93: 557-564, 2005.
7. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S and Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94: 435-442, 2002. (Pubitemid 34081374)
8. Miyamoto A, Umeshita K, Sakon M, Nagano H, Eguchi H, Kishimoto S, Dono K, Nakamori S, Gotoh M and Monden M: Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 15: 1447-1451, 2000. (Pubitemid 32052922)
9. Stuart K, Tessitore J and Huberman M: 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 19: 136-139, 1996.
10. Dash S, Prabhu R, Hazari S, Bastian F, Garry R, Zou W, Haque S, Joshi V, Regenstein FG and Thung SN: Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int 25: 580-594, 2005. (Pubitemid 40861908)
11. Theofilopoulos AN, Baccala R, Beutler B and Kono DH: Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336, 2005. (Pubitemid 40563172)
12. Bekisz J, Schmeisser H, Hernandez J, Goldman ND and Zoon KC: Human interferons alpha, beta and omega. Growth Factors 22: 243-251, 2004. (Pubitemid 40123402)
13. Rosewicz S, Detjen K, Scholz A and von Marschall Z: Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 80: 85-93, 2004. (Pubitemid 39382376)
14. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ and Fidler IJ: Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 8: 2413-2422, 2002. (Pubitemid 34753617)
15. Roisman LC, Jaitin DA, Baker DP and Schreiber G: Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol 353: 271-281, 2005.
16. Lamken P, Gavutis M, Peters I, van der Heyden J, Uze G and Piehler J: Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1. J Mol Biol 350: 476-488, 2005. (Pubitemid 40828908)
17. Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K, Konishi T, Nakamura H, Korenaga M, Okuda M and Okita K: Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 11: 136-140, 2004. (Pubitemid 38365764)
18. Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D and Croze E: Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 111: 32-42, 2004. (Pubitemid 38859280)
19. Ismail A, van Groeningen CJ, Hardcastle A, Ren Q, Aherne GW, Geoffroy F, Allegra CJ and Grem JL: Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma. Mol Pharmacol 53: 252-261, 1998. (Pubitemid 28099735)
20. Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC and Markowitz AB: Phase I and pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alpha-2b in patients with advanced cancer. J Clin Oncol 11: 751-761, 1993.
21. Schwartz EL, Hoffman M, O'Connor CJ and Wadler S: Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 182: 1232-1239, 1992.
22. Yee LK, Allegra CJ, Steinberg SM and Grem JL: Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during therapy with 5-fluorouracil, leucovorin and interferon alpha-2a. J Natl Cancer Inst 84: 1820-1825, 1992.
23. Yao Y, Kubota T, Sato K, Takeuchi H, Kitai R and Matsukawa S: Interferons up-regulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells. J Neurooncol 72: 217-223, 2005. (Pubitemid 40867403)
24. Dou J, Iwashita Y, Sasaki A, Kai S, Hirano S, Ohta M and Kitano S: Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression. Liver Int 25: 148-152, 2005. (Pubitemid 40298257)
25. Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, Dono K, Nakamori S, Umeshita K, Sakon M and Monden M: Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6: 2881-2890, 2000. (Pubitemid 30482131)
26. Murakami T: Establishment and characterization of human hepatoma cell line (KIM-1). Acta Hepatol Jpn 25: 532-539, 1984.
27. Yano H, Kojiro M and Nakashima T: A new human hepatocellular carcinoma cell line (KYN-1) with a transformation to adenocarcinoma. In Vitro Cell Dev Biol 22: 637-646, 1986. (Pubitemid 17022420)
28. Yano H, Maruiwa M, Murakami T, Fukuda K, Ito Y, Sugihara S and Kojiro M: A new human pleomorphic hepatocellular carcinoma cell line, KYN-2. Acta Pathol Jpn 38: 953-966, 1988.
29. Murakami T, Maruiwa M, Fukuda K, Kojiro M, Tanaka M and Tanikawa K: Characterization of a new human hepatoma cell line (KYN-3) derived from the ascites of the hepatoma patient. Proceedings of the Japanese Cancer Association. Jpn J Cancer Res 292, 1988.
30. Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M and Kojiro M: Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 18: 320-327, 1993. (Pubitemid 23225103)
31. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44: 1299-1305, 1997. (Pubitemid 27249311)
32. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
33. Kondo M, Nagano H, Wada H, Damdinsuren B, Yamamoto H, Hiraoka N, Eguchi H, Miyamoto A, Yamamoto T, Ota H, Nakamura M, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M and Monden M: Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res 11: 1277-1286, 2005.